Disease-free survival as an end-point in the treatment of solid tumours - Perspectives from clinical trials and clinical practice

作者：Robinson Andrew G^*; Booth Christopher M; Eisenhauer Elizabeth A

来源：European Journal of Cancer, 2014, 50(13): 2298-2302.

DOI：10.1016/j.ejca.2014.05.016

• Clinical trials
• Patient perspectives
• Disease-free survival
• Drug approval
• Solid tumours

Disease-free survival (DFS) is an end-point for an increasing number of clinical trials in adjuvant and curative intent cancer treatment informing both regulatory bodies and clinical practice. DFS is seen both as a surrogate end-point and as an end-point in itself in clinical trials. Understanding the history of DFS, and some of the assumptions, limitations, and vulnerabilities for studies designed with this primary end-point are required. This commentary reviews recent drug approvals for anti-cancer agents in solid tumours in the adjuvant and curative settings, and considers the meaning of DFS from the perspectives of clinical trials and clinical practice.

• 出版日期2014-9